FIP makes it a priority to publish the latest developments in pharmacy practice, pharmaceutical sciences, related global news and prominent events. Our multi-media approach to keeping members, partners and peers informed of what is and will be affecting their area of practice or science is key to keeping information flowing through the FIP network.
- Pharmacists’ authority in pharmaceutical product selection: Therapeutic interchange and substitution
The purpose of this document is to provide a set of recommendations on therapeutic interchange and substitution of pharmaceutical products, including with biosimilars.
- The role of pharmacists in reducing harm associated with drugs of abuse
This statement calls on governments to work more with pharmacists on providing harm reduction services and fully involve them in the development of any policies regarding medical or recreational cannabis
- Pharmacy: Gateway to care (2017, Seoul)
This policy statement outlines the importance of the full involvement of pharmacists in self care and replaces FIP’s 1996 statement “Self care including self medication — the professional role of the pharmacist”. It calls for pharmacists to be fully incorporated into health systems both for the prevention and management of illness, and for them to be properly remunerated for delivery of their self-care services. The new statement also makes a number of recommendations for pharmacy organisations and pharmacists.
- Role of the pharmacist in disaster management (2017, Seoul)
This statement makes clear pharmacists’ ethical duty to accept responsibility, as health care professionals, for providing aid to others in disaster situations, and for having plans in place to respond appropriately in the event of a natural or man-made disaster and to limit its impact.
- Strategic development of medicines information for the benefit of patients and users of medicines (Seoul, 2017)
This statement is an update to the federation’s 2008 statement “Medicines information for patients”. In particular, it highlights the importance of the strategic development of medicines information, and describes short-, medium- and long-term outcomes of this approach.
- Control of Antimicrobial Resistance (AMR) (Seoul, 2017)
This policy made a number of new recommendations to governments and pharmacists, reflecting developments FIP’s last statement on this topic in 2008, which include the declaration of antimicrobial resistance as a public health emergency and new global policies and commitments against the escalating threat to the control of infectious diseases.
- Environmentally sustainable pharmacy practice: Green pharmacy (2016, Buenos Aires)
This policy statements makes clear that pharmacists and pharmaceutical scientists must take responsibility for mitigating the environmental consequences of medicines, and this responsibility encompasses the entire course of medicines use, from manufacture and distribution to prescribing and dispensing, and to disposal and reduction of the discharge of metabolites of medicines into the environment. It sets out a number of recommended actions for FIP member organisations (national professional associations of pharmacy and pharmaceutical sciences), schools of pharmacy, individual pharmacists and governments. It also highlights the contribution non-adherence makes to medicines waste.
- The Effective Utilization of Pharmacists in Improving Maternal, Newborn and Child Health (MNCH) (2013, Dublin)
This policy document focuses on the effective contribution of pharmacists in improving maternal, newborn and child health.
- FIP Centennial Declaration (2012, Amsterdam)
- Collaborative Pharmacy Practice (2010, Lisbon)
- Control of Antimicrobial Medicines Resistance (2008, Basel)
- Medicines Information for Patients (2008, Basel)
- Quality of Medicines used for Children (2008, Basel)
- The Role Of The Pharmacist In Pharmacovigilance (2006, Brazil)
- The Role Of The Pharmacist In the Prevention And Treatment Of Chronic Disease (2006, Brazil)
- Improving Access to Medicines in Developing Countries (2005, Cairo)
- Point of Care Testing in Pharmacies (2004, New Orleans)
- Counterfeit Medicines (2003, Sydney)
- The Role of the Pharmacist in Promoting a Future Free of Tobacco (2003, Sydney)
- Good Practice in Donations of Medicines (1997, Vancouver)
- The Pharmacist's Authority in Product Selection ― Therapeutic Interchange and Generic Substitution (1997, Vancouver)
Good Storage and Distribution Practices for Pharmaceutical Products in Hospitals
FIP’s Hospital Pharmacy Section is organising a webinar on “Good storage and distribution practices for pharmaceutical products in hospitals”.
The correct storage and distribution and the continuous improvement of the processes involved in the supply chain from the acquisition to the administration or use of pharmaceutical products in hospitals, have a direct economic impact and improves quality assurance in patients care.
1. Understand variables that affect the stability of pharmaceutical products.
2. Understand storage and distribution processes.
3. Evaluate good storage and distribution practices that improves quality processes.
4. Highlight new technologies that benefit good practices for pharmaceutical products.
- Define variables that affect the stability of pharmaceutical products.
- Define storage and distribution processes for pharmaceutical products.
- Provide examples of good practices.
- Present new technologies that benefit good practices of storage and distribution.
Good Distribution Practices: Securing the Supply Chain
MEPS is hosting a webinar on the topic of Good Distribution Practices which will cover all aspects of the storage/distribution chain.
The Distribution chain has always had a great impact on the efficiency and integrity of the pharmaceutical manufacturing process, as well as safety in the ultimate use by the consumer.
Good Distribution Practice refers to the regulatory guidelines governing the wholesale distribution of medicinal products to ensure their quality and integrity is maintained throughout the supply chain from the manufacturer to the end user.
This webinar builds on a previous one on Good Distribution Practices.
At the end of this webinar the participants will be able to:
1. Understand the factors affecting Good Distribution Practices
Panellist: Dr Michael Anisfield, President and Senior Consultant, Globepharm Consulting
Chair: Mr Steve Shaddock (Vice President of MEPS)
This webinar is open to everyone free of charge.
Data privacy: All information requested is for use in compliance with applicable international privacy protection legislation. By completing the registration form, the participant requests that FIP uses this data to keep the participant informed of FIP activities and enhance their participation in those activities, understanding that the participant’s contact and demographic details may be made available to third parties deemed appropriate by the FIP; and, since FIP is an international organization, may be processed in any nation of the world. See the following data privacy statement: https://www.fip.org/glasgow2018/privacy-statement/
In a few days after the webinar, the recorded video of the webinar for individual FIP members will be available here: https://www.fip.org/webinars
Not a member yet? Register here: http://www.fip.org/membership?page=membership_info
We are looking forward to seeing you at the webinar.